Zavedení PSA testu na počátku osmdesátých let způsobilo převrat v diagnostice karcinomu prostaty. Testování PSA vyvolalo prudký nárůst počtu diagnostikovaných případů. Autoři článku hodnotí výsledky dvou zásadních studií, které se zabývají dopadem screeningu na mortalitu na karcinom prostaty: evropské studie ERSPC (the European Randomized Study of Screening for Prostate Cancer) a americké studie PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial).

The advent of prostate-specific antigen (PSA) testing in the early 1980s revolutionized the diagnosis of prostate cancer. As a result of PSA testing, there has been a surge in the number of prostate cancer dia - gnoses. This review examines the results of 2 recent landmark trials that studied the effect of screening on prostate cancer mortality: the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US-based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

• Keywords
• PSA screening,
• MeSH
• Early Detection of Cancer history   methods   utilization   MeSH
• Quality of Life MeSH
• Humans MeSH
• Meta-Analysis as Topic MeSH
• Multicenter Studies as Topic MeSH
• Prostatic Neoplasms diagnosis   prevention & control   MeSH
• Mass Screening history   methods   utilization   MeSH
• Primary Prevention methods   trends   MeSH
• Prostate-Specific Antigen history   isolation & purification   MeSH
• Practice Guidelines as Topic MeSH
• Statistics as Topic MeSH
• Age Factors MeSH
• Check Tag
• Humans MeSH

• MeSH
• Disease Management MeSH
• Men MeSH
• Prostatic Neoplasms history   therapy   MeSH
• Publication type
• Collected Work MeSH

• Conspectus
• Patologie. Klinická medicína
• NML Fields
• urologie
• andrologie
• onkologie

• MeSH
• Adrenergic alpha-Antagonists therapeutic use   MeSH
• Prostatic Hyperplasia diagnosis   MeSH
• Pathological Conditions, Signs and Symptoms MeSH
• Publication type
• Congress MeSH

• Conspectus
• Patologie. Klinická medicína
• NML Fields
• urologie